NR3C2 and diabetic kidney disease: A recent rapid expansion of treatment options include sodium-glucose co-transporter-2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists, which have demonstrated additional protective effects for the kidneys when used in addition to the standard therapy with RAS inhibitors, even in people with advanced DKD.